目的 探討尿毒清顆粒聯(lián)合非布司他治療高尿酸血癥的臨床療效。方法 選取2014年3月—2016年3月在駐馬店市中心醫(yī)院治療的高尿酸血癥患者140例，隨機(jī)分為對(duì)照組（70例）和治療組（70例）。對(duì)照組患者口服非布司他片，40 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服尿毒清顆粒，5 g/次，4次/d。兩組患者均經(jīng)過(guò)12周治療。觀察兩組患者臨床療效，比較治療前后兩組患者血清黃嘌呤氧化酶（XOD）、尿酸（BUA）、血肌酐（Scr）、尿素氮（BUN）、血清炎性因子水平以及血清NO和ET-1水平。結(jié)果 對(duì)照組臨床總有效率為87.14%，顯著低于治療組的97.14%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清XOD、BUA、Scr、BUN水平均明顯降低（P<0.05）；且治療組比對(duì)照組降低的更明顯（P<0.05）。治療后，兩組患者血清白細(xì)胞介素-1β（IL-1β）、髓過(guò)氧化物酶（MPO）、可溶性細(xì)胞間黏附分子-1（sICAM-1）、腫瘤壞死因子-α（TNF-α）水平均明顯降低（P<0.05）；且治療組患者血清炎性因子水平明顯低于對(duì)照組（P<0.05）。治療后，兩組患者血清NO水平顯著升高，內(nèi)皮素-1（ET-1）水平顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者NO和ET-1水平明顯優(yōu)于對(duì)照組（P<0.05）。結(jié)論 尿毒清顆粒聯(lián)合非布司他治療高尿酸血癥可有效降低機(jī)體炎癥反應(yīng)，改善血管內(nèi)皮功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Niaoduqing Granules combined with febuxostat in treatment of hyperuricemia. Methods Patients (140 cases) with hyperuricemia in Zhumadian Central Hospital from March 2014 to March 2016 were randomly divided into control (70 cases) and treatment (70 cases) groups. Patients in the control group were po administered with Febuxostat Tablets, 40 mg/time, once daily. Patients in the treatment group were po administered with Niaoduqing Granules on the basis of the control group, 5 g/time, four times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the serum XOD, BUA, Scr, BUN, serum inflammatory factors, serum NO and ET-1 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.14%, which was significantly lower than 97.14% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the XOD, BUA, Scr and BUN levels in two groups were significantly decreased (P < 0.05). And these indexes level in the treatment group decreased more significantly than that in the control group (P < 0.05). After treatment, the IL-1β, MPO, sICAM-1 and TNF-α levels in two groups were significantly decreased (P < 0.05). And the serum inflammatory factors in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum NO level in two groups was significantly increased, but ET-1 level was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serum NO and ET-1 level in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Niaoduqing Granules combined with febuxostat in treatment of hyperuricemia can effectively reduce the inflammatory reaction and improve the vascular endothelial function, which has a certain clinical application value.